Literature DB >> 28831571

The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant.

Ben Sessa1.   

Abstract

Given the plethora of new studies and published papers in the scientific press and the increasingly emerging presence of articles about positive psychedelic experiences appearing in the popular media, there is little doubt that we are in the midst of a Psychedelic Renaissance. The classical psychedelic drugs LSD and psilocybin and the entactogen MDMA are showing promise as tools to assist psychotherapy for a wide range of mental disorders, with multiple pilot studies demonstrating their safety and efficacy. In this article, the author describes how MDMA in particular has inherent characteristics that make it well suited for assisting trauma-focused psychotherapy in a population of patients who have experienced child abuse. But despite these advances, there remain many obstacles ahead of the widespread mainstream acceptance of psychedelic medicines. The author argues that the Misuse of Drugs Act 1971 is one such obstacle. Other impediments include a prevailing attitude of pseudoscience and rigidity from within the non-scientific psychedelic community itself. Resolution of these conflicts must be sought if medicine and society are to see psychedelics gaining a place in mainstream culture and science.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28831571     DOI: 10.1007/s00213-017-4713-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.415


  49 in total

1.  An attachment perspective on psychopathology.

Authors:  Mario Mikulincer; Philip R Shaver
Journal:  World Psychiatry       Date:  2012-02       Impact factor: 49.548

2.  MDMA enhances "mind reading" of positive emotions and impairs "mind reading" of negative emotions.

Authors:  Cédric M Hysek; Gregor Domes; Matthias E Liechti
Journal:  Psychopharmacology (Berl)       Date:  2012-01-27       Impact factor: 4.530

3.  MDMA, politics and medical research: have we thrown the baby out with the bathwater?

Authors:  Ben Sessa; David J Nutt
Journal:  J Psychopharmacol       Date:  2007-11       Impact factor: 4.153

4.  An investigation of the subacute effects of ecstasy on neuropsychological performance, sleep and mood in regular ecstasy users.

Authors:  A Pirona; M J Morgan
Journal:  J Psychopharmacol       Date:  2009-04-07       Impact factor: 4.153

5.  A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy").

Authors:  M R Thompson; P D Callaghan; G E Hunt; J L Cornish; I S McGregor
Journal:  Neuroscience       Date:  2007-03-23       Impact factor: 3.590

6.  Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naïve healthy volunteers.

Authors:  F X Vollenweider; A Gamma; M Liechti; T Huber
Journal:  Neuropsychopharmacology       Date:  1998-10       Impact factor: 7.853

7.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Authors:  Matthew W Johnson; Albert Garcia-Romeu; Mary P Cosimano; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2014-09-11       Impact factor: 4.153

8.  Posttraumatic stress disorder in the National Comorbidity Survey.

Authors:  R C Kessler; A Sonnega; E Bromet; M Hughes; C B Nelson
Journal:  Arch Gen Psychiatry       Date:  1995-12

Review 9.  Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis.

Authors:  Mathew Hoskins; Jennifer Pearce; Andrew Bethell; Liliya Dankova; Corrado Barbui; Wietse A Tol; Mark van Ommeren; Joop de Jong; Soraya Seedat; Hanhui Chen; Jonathan I Bisson
Journal:  Br J Psychiatry       Date:  2015-02       Impact factor: 9.319

10.  Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

Authors:  Robin L Carhart-Harris; Mark Bolstridge; James Rucker; Camilla M J Day; David Erritzoe; Mendel Kaelen; Michael Bloomfield; James A Rickard; Ben Forbes; Amanda Feilding; David Taylor; Steve Pilling; Valerie H Curran; David J Nutt
Journal:  Lancet Psychiatry       Date:  2016-05-17       Impact factor: 27.083

View more
  8 in total

1.  Research ethics aspects of experimentation with LSD on human subjects: a historical and ethical review.

Authors:  Kristóf János Bodnár; Péter Kakuk
Journal:  Med Health Care Philos       Date:  2019-06

2.  Psychedelics as Reemerging Treatments for Anxiety Disorders: Possibilities and Challenges in a Nascent Field.

Authors:  Franklin King; Rebecca Hammond
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-06-17

3.  Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.

Authors:  Otto Simonsson; Simon B Goldberg
Journal:  J Psychoactive Drugs       Date:  2022-01-09

4.  DARK Classics in Chemical Neuroscience: NBOMes.

Authors:  Christian B M Poulie; Anders A Jensen; Adam L Halberstadt; Jesper L Kristensen
Journal:  ACS Chem Neurosci       Date:  2019-11-12       Impact factor: 5.780

5.  Associations between lifetime classic psychedelic use and markers of physical health.

Authors:  Otto Simonsson; James D Sexton; Peter S Hendricks
Journal:  J Psychopharmacol       Date:  2021-03-09       Impact factor: 4.153

6.  The Effects of Drugs on Behavior Maintained by Social Contact: Role of Monoamines in Social Reinforcement.

Authors:  Jessica L Sharp; Mark A Smith
Journal:  Front Behav Neurosci       Date:  2022-02-21       Impact factor: 3.617

7.  From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner.

Authors:  Hannes Kettner; Sam Gandy; Eline C H M Haijen; Robin L Carhart-Harris
Journal:  Int J Environ Res Public Health       Date:  2019-12-16       Impact factor: 3.390

Review 8.  Psychedelics and health behaviour change.

Authors:  Pedro J Teixeira; Matthew W Johnson; Christopher Timmermann; Rosalind Watts; David Erritzoe; Hannah Douglass; Hannes Kettner; Robin L Carhart-Harris
Journal:  J Psychopharmacol       Date:  2021-05-29       Impact factor: 4.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.